78 results on '"Ghosal, Samit"'
Search Results
2. Review for "Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post‐hoc analysis of the EMMY trial"
3. Review for "Meta‐analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin"
4. The Renal Composite Benefit of Sodium Glucose Co-Transporter 2 Inhibitors Should Ideally Be Assessed Based on a Standardised Definition: A Meta-Analysis of Randomised Controlled Trials
5. P15 Comparative efficacy of pioglitazone and saroglitazar in non-alcoholic fatty liver disease: a Bayesian network meta-analysis
6. Exploring the comparative cardiovascular death benefits of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring
7. Conducting and Reporting Meta-analysis: A Checklist for Reviewers
8. EMPAGLIFLOZIN & CANAGLIFOZIN HAVE SUPERIOR CARDIOVASULAR DEATH BENEFITS IN TYPE 2 DIABETIC PATIETS WITH ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS. A META-ANALYSIS
9. Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
10. Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis
11. Using machine learning to assess cardiovascular risk in type 2 diabetes mellitus patients without established cardiovascular disease: The MARK-2 analysis
12. The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): A meta-analysis of observational studies
13. Glucagon-related advancements in diabetes therapy
14. Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis
15. LBODP046 Reduction In "Cardiovascular Death Or Hospitalisation For Heart Failure" With Sglt-2is Is Dependent On Weight Reduction: A Meta-regression Analysis
16. Survey to Specify SGLT2 Inhibitor Choice in T2DM Management
17. Review for "Intensive glucose control and recurrent cardiovascular events: 14‐year follow‐up investigation of the ACCORDION study"
18. Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis
19. Review for "Intensive glucose control and recurrent cardiovascular events: 14‐year follow‐up investigation of the ACCORDION study"
20. The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs
21. Using machine learning to assess cardiovascular risk in T2DM patients without established cardiovascular disease: The MARK-2 analysis
22. Frequency of ST-segment elevation acute myocardial infarction in patients with Type 2 Diabetes Mellitus
23. The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis
24. A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients With Polycystic Ovary Syndrome
25. The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis
26. Conducting and reporting meta-analysis: A checklist for reviewers
27. Clinical characteristics of T2DM patients diagnosed with HFpEF: An Indian pilot survey
28. A machine-learning tool to assess CV risk inT2DM patients without established CVD: The MARK-2 analysis
29. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
30. A Meta-Analysis of the Effects of Glucagon-Like-Peptide 1 Receptor Agonist (GLP1-RA) in Nonalcoholic Fatty Liver Disease (NAFLD) With Type 2 Diabetes (T2D)
31. Review for "Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?"
32. A Target HbA1c Between 7 and 7.7% Reduces Microvascular and Macrovascular Events in T2D Regardless of Duration of Diabetes: a Meta-Analysis of Randomized Controlled Trials
33. Review for "Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?"
34. A target HbA1c between 7 – 7.7% reduces macrovascular events in T2D regardless of duration of diabetes – a meta-analysis of randomized controlled trials
35. Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes
36. Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials
37. Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials
38. “Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors – A survey"
39. Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic in India: A cohort analysis
40. Selecting antihyperglycemic agents with proven safety: A must in COVID-19 era
41. Reply to letter to the editor regarding article: Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis (Ghosal et al.)
42. Linear Regression Analysis to predict the number of deaths in India due to SARS-CoV-2 at 6 weeks from day 0 (100 cases - March 14th 2020)
43. Rapid sputum testing and not thermal screening alone should be the first-line screening test at airports: A Bayesian analysis
44. Impact of complete lockdown on total infection and death rates: A hierarchical cluster analysis
45. Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis
46. Is it Worth CANVASing for CREDENCE? A Benefit-risk Analysis
47. Impact of complete lock-down on total infection and death rates: A hierarchical cluster analysis
48. Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice
49. The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): A meta-analysis
50. Frequency of testing for COVID 19 infection and the presence of higher number of available beds per country predict outcomes with the infection, not GDP of the country – A descriptive statistical analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.